FKBP5 Gene Variants as Predictors for Antidepressant Response in Individuals with Major Depressive Disorder Who Have Experienced Childhood Trauma. A Systematic Review

  • Natalie Wietfeldt Saba University
Keywords: Pharmacogenetics, Depressive Disorder, Major, Adult Survivors of Child Adverse Events

Abstract

FKBP5 gene variants may predict antidepressant treatment response in individuals with Major Depressive Disorder. PubMed and Web of Science were searched systematically for articles studying individuals who had received a diagnosis of Major Depressive Disorder (MDD) and were given antidepressant treatment. Inclusion criteria were studies that researched FKBP5 and its variants and focused on antidepressant treatment response. Previous studies support a potential underlying epigenetic mechanism, demethylation at FKBP5 polymorphisms (rs1360780, rs3800373, rs9470080, and rs4713916) after experiencing childhood trauma, leading to increased hypothalamic-pituitary-adrenal (HPA) axis sensitivity and a propensity for the development of MDD. These polymorphisms informed the search, but additional polymorphisms (rs9380514, rs352428) were also considered. Studies conducted prior to 2008, reviews, meta-analyses, editorials, and non-research based articles were excluded. Studies examined in this article link FKBP5 polymorphisms (rs4713916) and FKBP5 RNA levels with positive antidepressant response. Variants rs1360780, rs3800373, and rs9470080 were associated with both positive response and non-response or lack of remission. Variants rs9380514, rs352428, and rs936882 were associated with poor response to antidepressant treatment or non-remission. Further insights into the role FKBP5 plays in development and antidepressant treatment response may be aided by future studies focused on individuals who previously experienced childhood trauma and later developed MDD.

References

Substance Abuse and Mental Health Services Administration. (2018). Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, MD: Center for Behavioral Health Statistics and Quality. Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data.

Pratt LA, Brody DJ, Gu Q. Antidepressant Use among Persons Aged 12 and Over: United States, 2011-2014. NCHS Data Brief. Number 283. National Center for Health Statistics. 2017 Aug.

Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature genetics. 2004 Dec;36(12):1319.

Rao S, Yao Y, Ryan J, Li T, Wang D, Zheng C, Xu Y, Xu Q. Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis. Scientific reports. 2016 Sep 7;6:32687.

Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2007 Dec 5;144(8):1097-8.

American Psychiatric Association. (2019). American Psychiatric Association Council on Research’s Response to JRC Request for a Resource Document for Pharmacogenomics. Retrieved from <http://sirf-online.org/wp-content/uploads/2019/01/APAStatement.pdf>

Ising M, Scheuer S, Belcredi P, Uhr M, Holsboer F. S74. Perspective of Personalized Drug Treatment in Depression. Biological Psychiatry. 2018 May 1;83(9):S375-6.

Tokuda T, Yoshimoto J, Shimizu Y, Okada G, Takamura M, Okamoto Y, Yamawaki S, Doya K. Identification of depression subtypes and relevant brain regions using a data-driven approach. Scientific reports. 2018 Sep 20;8(1):14082.

Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000 Nov;23(5):477.

Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends in neurosciences. 2008 Sep 1;31(9):464-8.

Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, Stender J, Barnow S, John U, Teumer A, Biffar R. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology. 2011 Sep;36(10):1982.

Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, Pace TW, Mercer KB, Mayberg HS, Bradley B, Nemeroff CB. Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions. Nature neuroscience. 2013 Jan;16(1):33.

Lavebratt C, Åberg E, Sjöholm LK, Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. Journal of affective disorders. 2010 Sep 1;125(1-3):249-55.

Tyrka AR, Ridout KK, Parade SH, Paquette A, Marsit CJ, Seifer R. Childhood maltreatment and methylation of FK506 binding protein 5 gene (FKBP5). Development and psychopathology. 2015 Nov;27(4pt2):1637-45.

Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009 Dec 1;34:S186-95.

Farrell C, Doolin K, O’Leary N, Jairaj C, Roddy D, Tozzi L, Morris D, Harkin A, Frodl T, Nemoda Z, Szyf M. DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic–pituitary–adrenal axis activity and to early life emotional abuse. Psychiatry research. 2018 Jul 1;265:341-8.

Matosin N, Halldorsdottir T, Binder EB. Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: the FKBP5 model. Biological psychiatry. 2018 May 15;83(10):821-30.

Menke A, Lehrieder D, Fietz J, Leistner C, Wurst C, Stonawski S, Reitz J, Lechner K, Busch Y, Weber H, Deckert J. Childhood trauma dependent anxious depression sensitizes HPA axis function. Psychoneuroendocrinology. 2018 Dec 1;98:22-9.

Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. The Journal of Clinical Endocrinology & Metabolism. 2003 Jan 1;88(1):277-84.

Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene–stress–epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology. 2016 Jan;41(1):261.

Koenen KC, Saxe G, Purcell S, Smoller JW, Bartholomew D, Miller A, Hall E, Kaplow J, Bosquet M, Moulton S, Baldwin C. Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Molecular psychiatry. 2005 Dec;10(12):1058.

Mehta D, Gonik M, Klengel T, Rex-Haffner M, Menke A, Rubel J, Mercer KB, Pütz B, Bradley B, Holsboer F, Ressler KJ. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Archives of general psychiatry. 2011 Sep 5;68(9):901-10.

Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology. 2010 Jul;35(8):1674.

Zimmermann P, Brückl T, Nocon A, Pfister H, Binder EB, Uhr M, Lieb R, Moffitt TE, Caspi A, Holsboer F, Ising M. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. American Journal of Psychiatry. 2011 Oct;168(10):1107-16.

Grabe HJ, Wittfeld K, Van der Auwera S, Janowitz D, Hegenscheid K, Habes M, Homuth G, Barnow S, John U, Nauck M, Völzke H. Effect of the interaction between childhood abuse and rs1360780 of the FKBP5 gene on gray matter volume in a general population sample. Human brain mapping. 2016 Apr;37(4):1602-13.

Tozzi L, Carballedo A, Wetterling F, McCarthy H, O'keane V, Gill M, Morris D, Fahey C, Meaney J, Frodl T. Single-nucleotide polymorphism of the FKBP5 gene and childhood maltreatment as predictors of structural changes in brain areas involved in emotional processing in depression. Neuropsychopharmacology. 2016 Jan;41(2):487.

Tozzi L, Farrell C, Booij L, Doolin K, Nemoda Z, Szyf M, Pomares FB, Chiarella J, O'Keane V, Frodl T. Epigenetic changes of FKBP5 as a link connecting genetic and environmental risk factors with structural and functional brain changes in major depression. Neuropsychopharmacology. 2018 Apr;43(5):1138.

Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology. 2013 Feb;38(3):377.

Banach E, Szczepankiewicz A, Leszczynska-Rodziewicz A, Pawlak J, Dmitrzak-Weglarz M, Zaremba D, Twarowska-Hauser J. Venlafaxine and sertraline does not affect the expression of genes regulating stress response in female MDD patients. Psychiatr. Pol. 2017 Dec 30;51(6):1029-38.

Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S. The FKBP5-gene in depression and treatment response—an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR* D) Cohort. Biological psychiatry. 2008 Jun 15;63(12):1103-10.

Zobel A, Schuhmacher A, Jessen F, Höfels S, Von Widdern O, Metten M, Pfeiffer U, Hanses C, Becker T, Rietschel M, Scheef L. DNA sequence variants of the FKBP5 gene are associated with unipolar depression. International Journal of Neuropsychopharmacology. 2010 Jun 1;13(5):649-60.

Stamm TJ, Rampp C, Wiethoff K, Stingl J, Mössner R, O′ Malley G, Ricken R, Seemüller F, Keck M, Fisher R, Gaebel W. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. Journal of Psychopharmacology. 2016 Jan;30(1):40-7.

Fabbri C, Corponi F, Albani D, Raimondi I, Forloni G, Schruers K, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S. Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018 Feb 2;81:203-10.

Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenetics and genomics. 2013 Mar;23(3):156.

Hähle A, Merz S, Meyners C, Hausch F. The many faces of FKBP51. Biomolecules. 2019 Jan;9(1):35.

Ising M, Maccarrone G, Brückl T, Scheuer S, Hennings J, Holsboer F, Turck CW, Uhr M, Lucae S. FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression. International journal of molecular sciences. 2019 Jan;20(3):485.

Published
2020-05-22
How to Cite
Wietfeldt, N. (2020). FKBP5 Gene Variants as Predictors for Antidepressant Response in Individuals with Major Depressive Disorder Who Have Experienced Childhood Trauma. A Systematic Review. International Journal of Medical Students. https://doi.org/10.5195/ijms.2020.437
Section
Review